Testing a new drug for AML with FLT3 or spliceosome mutations
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your AML has come back after or did not respond to your first treatment.
- You have a FLT3 mutation (like FLT3-ITD or FLT3-TKD) OR a spliceosome mutation (such as SF3B1, SRSF2, U2AF1, or ZRSR2).
- If you have a FLT3 mutation, you must have tried or been unable to use a drug called Gilteritinib.
- You are generally in good health (able to care for yourself and walk around, ECOG 0-2).
- Your liver and kidney function are within certain limits (checked by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called revumenib combined with a strong chemotherapy regimen (7+3) and midostaurin for people with newly diagnosed AML that has specific gene mutations (FLT3 and NPM1). The goal is to see if this combination works better than standard treatments.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
This trial tests a targeted therapy that specifically attacks leukemia cells with the FLT3-ITD gene change. If you have this mutation, the goal is to see if adding this drug to standard chemotherapy improves your chances of going into remission.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial tests a combination of two targeted drugs, SNDX-5613 and gilteritinib, for people whose AML has come back or hasn't responded to treatment. It is for those with an FLT3 gene mutation plus another specific genetic change like NPM1 or MLL. The study aims to see if this two-drug approach works better when used together.
Hear when a new AML With Gene Mutations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.